期刊
CHEMICAL COMMUNICATIONS
卷 59, 期 62, 页码 9457-9468出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d3cc02283h
关键词
-
This article offers a personal account of the discovery and development of a photosensitizer for photodynamic therapy of cancer. It focuses on the chemical aspects of drug discovery and development, including the chemical landscape at the time of discovery, the breakthrough offered by stable bacteriochlorins, challenges in synthesizing high purity products for preclinical studies, the relationship between molecular structure and pharmacology in PDT, and the interpretation of preclinical data and management of unexpected results. Special attention is given to the implications of atropisomerism and immune responses in PDT.
We offer a personal account of the discovery and development of a photosensitizer for photodynamic therapy (PDT) of cancer, from bench to bedside. We emphasize the more chemical aspects of drug discovery and drug development, namely the chemical landscape at the time of the discovery, the breakthrough in the field offered by stable bacteriochlorins, the challenges of synthesising a significant amount of the product with high purity for preclinical studies, the factors that relate molecular structure to pharmacology in PDT, the mechanistic interpretation of preclinical data and the management of unexpected results. Special attention is given to the implications of atropisomerism and immune responses in PDT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据